DarioHealth Corp., a digital health company headquartered in New York, has been making significant strides in the health care sector, particularly within the Health Care Equipment & Supplies industry. As of November 10, 2026, the company’s stock was trading at a close price of $2.125 on the Nasdaq exchange, reflecting a notable fluctuation over the past year. The stock reached its 52-week high of $14.77 on November 19, 2025, but experienced a significant drop to its 52-week low of $1.695 on November 9, 2026. Despite these fluctuations, DarioHealth maintains a market capitalization of $23,420,000.
DarioHealth Corp. is renowned for its innovative approach to managing multi-chronic conditions through digital therapeutics platforms. These platforms are designed to provide personalized and dynamic interventions, leveraging data analytics and one-on-one coaching to address a range of health issues, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company’s commitment to user-centric solutions has positioned it as a leader in the digital health space.
The company’s financial metrics, however, indicate some challenges. With a price-to-earnings ratio of -2.65, DarioHealth reflects a period of financial adjustment, which is not uncommon for companies in the growth phase of digital health innovations. This negative ratio suggests that the company is currently not generating profits, a situation that can be attributed to the substantial investments required for research, development, and global expansion.
DarioHealth’s global reach is a testament to its strategic vision. By offering its services worldwide through its official website, the company has successfully expanded its customer base beyond the United States. This globalization strategy not only diversifies its market presence but also enhances its potential for growth in the rapidly evolving digital health sector.
In summary, DarioHealth Corp. continues to be a significant player in the health care industry, driven by its innovative digital therapeutics platforms and a strong focus on personalized health interventions. While the company faces financial challenges, its strategic initiatives and global expansion efforts position it well for future growth and success in the digital health landscape.
